Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab

Bagnasco, Diego;Bondi, Benedetta;Brussino, Luisa;Nicola, Stefania;Braido, Fulvio;et.al.
(2025) Journal of Personalized Medicine — Vol. 15, n° 2, p. 43 (2025)

Files

Switch Diego.pdf
  • Open Access
  • Adobe PDF
  • 1.32 MB
Download

Details

Authors
  • Bagnasco, Diegoorcid-logoRespiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
    Author
  • Bondi, BenedettaRespiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
    Author
  • Brussino, Luisaorcid-logoSCDU Immunology and Allergology, AO Ordine Mauriziano, 10128 Turin, Italy
    Author
  • Nicola, Stefaniaorcid-logoSCDU Immunology and Allergology, AO Ordine Mauriziano, 10128 Turin, Italy
    Author
  • Tiotiu-Cepuc, IulianaUCLouvain
    Author
  • Braido, FulvioRespiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
    Author
  • et. al.
Show more
Abstract
Background/Objectives: Severe allergic asthma is usually treated with omalizumab; however, this drug may not be effective for every patient. By its action, dupilumab could be an alternative in these patients. The objective of this study was to evaluate the efficacy of dupilumab in patients with severe allergic asthma, non-responsive to omalizumab, according to the maintenance of their oral corticosteroid (OCS) dose, an exacerbation rate decrease, or poor control of the disease, despite optimized treatment. Methods: A retrospective analysis of data from severe asthma clinics was performed, observing the efficacy of the switch to dupilumab in patients who experienced a failed treatment with omalizumab. Results: Forty-two patients were included. Dupilumab proved to be effective in patients who experienced a failed omalizumab treatment, with a significant reduction in the exacerbation number and OCS use. Furthermore, remission of the disease, according to the Severe Asthma Network of Italy (SANI) criteria, was achieved in 35 patients, with complete remission in 19 (45%) and partial remission in 16 (38%). The analysis of the predictors of the success of dupilumab therapy in achieving clinical remission, through univariate analysis of the data at baseline, showed that complete remission was more easily reached in patients with concomitant aspirin (ASA) intolerance or in those with nasal polyposis. Conclusions: Dupilumab is an effective drug for the treatment of patients with severe asthma with an allergic component, with better benefits in patients with an ASA intolerance or nasal polyposis.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bagnasco, D., Bondi, B., Brussino, L., Nicola, S., Cameli, P., Tiotiu-Cepuc, I., Guida, G., Gollinucci, C., Visca, D., Spanevello, A., Pini, L., Caminati, M., Senna, G., Caruso, C., Canevari, R., Bertolini, M., Fedele, S., Mincarini, M., Canonica, G., et al. (2025). Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab. Journal of Personalized Medicine, 15(2), 43. https://doi.org/10.3390/jpm15020043 (Original work published 2025)